Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
IXAQF (IXAQF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: IXAQF (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 8.61% | Avg. Invested days 79 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 85.60M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.03 | 52 Weeks Range 11.16 - 13.00 | Updated Date 05/3/2025 |
52 Weeks Range 11.16 - 13.00 | Updated Date 05/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.22 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -3.91% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 89140398 | Price to Sales(TTM) - |
Enterprise Value 89140398 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 5612490 | Shares Floating 1610376 |
Shares Outstanding 5612490 | Shares Floating 1610376 | ||
Percent Insiders 71.31 | Percent Institutions 11.25 |
Upturn AI SWOT
IXAQF
Company Overview
History and Background
IXAQF refers to iXBiopharma Ltd, founded in 2007 in Singapore. It is a pharmaceutical company focused on developing and commercializing novel, patent-protected, sublingual formulations of drugs. Its goal is to improve patient outcomes and experience.
Core Business Areas
- Wafermine: Sublingual formulation of ketamine for acute pain management in hospitals.
- Xativa: Sublingual formulation of sildenafil for treatment of erectile dysfunction.
Leadership and Structure
The leadership team consists of the CEO and key executives responsible for R&D, commercialization, and finance. Organizational structure is typical for a pharmaceutical company with departments covering drug development, manufacturing, and sales.
Top Products and Market Share
Key Offerings
- Wafermine: Sublingual ketamine wafer for acute pain management. Market share is currently being established in targeted hospitals. Competitors include traditional IV and IM ketamine formulations, as well as opioid-based pain medications.
- Xativa: Sublingual sildenafil film for erectile dysfunction. It has launched in Australia. Competitors include Viagra (sildenafil), Cialis (tadalafil), and other PDE5 inhibitors.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with significant R&D costs and long development timelines. It's constantly innovating with novel drug delivery methods to improve patient outcomes and experience.
Positioning
iXBiopharma focuses on niche markets with its sublingual drug delivery technology, aiming to differentiate itself through faster onset of action and improved patient convenience.
Total Addressable Market (TAM)
The total market value for pain management and erectile dysfunction medications is several billion dollars. IXAQF aims to capture a portion of this market with its innovative sublingual formulations.
Upturn SWOT Analysis
Strengths
- Proprietary sublingual drug delivery technology
- Patent-protected formulations
- Potential for faster onset of action
- Improved patient convenience
Weaknesses
- Limited resources compared to larger pharmaceutical companies
- Reliance on successful commercialization of a few key products
- Potential regulatory hurdles
- Geographic concentration in Asia-Pacific
Opportunities
- Expansion into new therapeutic areas
- Partnerships with larger pharmaceutical companies
- Further development of sublingual drug delivery platform
- Expansion into new geographic markets
Threats
- Competition from established pharmaceutical companies
- Generic drug entry
- Adverse clinical trial results
- Changing regulatory landscape
Competitors and Market Share
Key Competitors
- PFE
- LLY
- VTRS
Competitive Landscape
IXAQF competes with much larger pharmaceutical companies. Its sublingual technology offers a competitive advantage but requires significant marketing and sales efforts to gain market share.
Major Acquisitions
No notable acquisitions available at this time.
- Year: 2022
- Acquisition Price (USD millions): 0
- Strategic Rationale: Explain the strategic reasons behind the acquisition.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends can be evaluated from past financial results.
Future Projections: Future growth projections can be developed based on analyst estimates and market trends.
Recent Initiatives: Recent strategic initiatives include product launches in new markets, research and development projects, and partnership agreements.
Summary
iXBiopharma is a pharmaceutical company with proprietary sublingual drug delivery technology. It is focused on niche markets but faces stiff competition from larger firms. The company's success depends on the successful commercialization of its key products and strategic partnerships. Financial stability and efficient capital allocation will be necessary to grow and compete effectively. IXAQF's future depends on continued innovation and expansion into new markets.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Financial News Sources
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and does not constitute financial advice. The information provided is for informational purposes only, and the data may not be completely accurate or up-to-date. Investment decisions should be made with due diligence and the advice of a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About IXAQF
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-11-30 | CEO, CFO, COO & Director Mr. Noah Aptekar | ||
Sector Financial Services | Industry Shell Companies | Full time employees - | Website https://www.ixacq.com |
Full time employees - | Website https://www.ixacq.com | ||
IX Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It focuses on companies in technology, media and telecommunications, and information and communication technology industries, as well as companies operating in telecommunications infrastructure, internet and technology, and digital services sectors in Europe and other markets. The company was incorporated in 2021 and is based in London, United Kingdom. IX Acquisition Corp. is a subsidiary of IX Acquisition Sponsor LLC.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.